本文關(guān)鍵詞：中醫(yī)藥方劑在晚期肝癌患者疼痛減輕和生存期延長方面的作用　出處：《遼寧中醫(yī)雜志》2017年10期 　論文類型：期刊論文

  更多相關(guān)文章： 中醫(yī)藥方劑 肝癌晚期 疼痛 生存期

【摘要】：目的:探討中醫(yī)藥方劑的運(yùn)用在晚期肝癌患者疼痛減輕和生存期延長方面的作用。方法:選取89例晚期肝癌患者,按照病人治療意愿分成兩組,對照組35例,觀察組54例;對照組予以止痛等減癥支持治療,觀察組在對照組的基礎(chǔ)上予以中醫(yī)藥方劑辨證治療;患者疼痛情況主要以患者主觀感受和疼痛視覺模擬(VAS)評估,分別記錄兩組患者給藥前、后VAS評分和患者肝功能指標(biāo)及1月、2月、3月生存率。結(jié)果:兩組患者治療后疼痛均有顯著減輕(P0.05),但觀察組治療后第1月時(shí)VAS評分為(5.7±1.2)顯著低于對照組,P0.05,差異顯著,具有統(tǒng)計(jì)學(xué)意義;統(tǒng)計(jì)兩組生存率及生存時(shí)間,觀察組在1月、2月、3月時(shí)的生存率分別是88.89%、75.95%、66.67%均顯著高于對照組,P0.05,差異具有統(tǒng)計(jì)學(xué)意義;比較治療前、后1個(gè)月時(shí)兩組患者部分肝功能指標(biāo)(ALT、AST、Tb)及甲胎蛋白(AFP),治療后兩組指標(biāo)均有下降,觀察組ALT(93.2±11.5)U/L、AST(96.5±13.8)U/L、Tb(54.3±4.7)μmol/L、AFP(705±203)μg/L均低于對照組,P0.05,差異顯著,具有統(tǒng)計(jì)學(xué)意義。結(jié)論:中醫(yī)藥方劑可有效減輕肝癌晚期患者的疼痛,普遍延長生存期。
[Abstract]:Objective: to explore the effect of traditional Chinese medicine (TCM) on pain relief and survival time prolongation in patients with advanced liver cancer. Methods: 89 patients with advanced liver cancer were divided into two groups according to their intention to treat. 35 cases in control group and 54 cases in observation group; The control group was treated with pain relief and other symptomatic support therapy, while the observation group was treated with TCM prescription differentiation on the basis of the control group. The patients' pain was assessed by subjective feeling and visual analogue of pain. The VAS score and liver function were recorded before and after administration of the drug, January, February, respectively. Results: after treatment, the pain in both groups was significantly alleviated (P 0.05), but the VAS score in the observation group was significantly lower than that in the control group on January (5. 7 鹵1. 2). P0.05, the difference is significant, has the statistical significance; The survival rate and survival time of the two groups were 88.89 on January, February and March, respectively, and 66.67% of the two groups were significantly higher than the control group (P0.05). The difference is statistically significant. Before and one month after treatment, some liver function indexes of the two groups were compared with alt ASTT Tb) and AFP, and the indexes of both groups were decreased after treatment. In the observation group, the ALT(93.2 鹵11.5U / L ~ (-1) / L ~ (-1) / L ~ (-1) T _ (1) / L ~ (1) T _ (3) / L ~ (-1) T _ (B) was 54.3 鹵4.7 渭 mol/L. AFP(705 鹵203 渭 g / L was significantly lower than that of control group (P 0.05). Conclusion: TCM prescription can effectively relieve pain in patients with advanced liver cancer. The survival period is generally prolonged.
【作者單位】： 河北省中醫(yī)院脾胃病二科;河北醫(yī)科大學(xué)研究生學(xué)院;河北中醫(yī)學(xué)院研究生學(xué)院;
【基金】：河北省中醫(yī)藥管理局科研計(jì)劃項(xiàng)目(2014171)
【分類號】：R273
【正文快照】： 原發(fā)性肝癌(primary liver cancer,PLC)是發(fā)生在肝細(xì)胞或肝內(nèi)膽管細(xì)胞的惡性腫瘤(區(qū)別于繼發(fā)性肝癌),在我國是十分常見的惡性腫瘤之一,預(yù)后極差,自然生存期僅2~6個(gè)月[1],死亡率在消化道腫瘤中排在胃癌和食管癌之后,位居第三。PLC可發(fā)生于任何年齡,40~49歲是高發(fā)年齡,男女比例

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 呂志連;;治療肝癌一得[J];浙江中醫(yī)藥大學(xué)學(xué)報(bào);1992年01期

2 程濤;;厚樸生姜半夏甘草人參湯治療肝癌晚期腹脹56例[J];光明中醫(yī);2013年02期

3 白廣德;;中醫(yī)及中西醫(yī)結(jié)合治療原發(fā)性中晚期肝癌的研究進(jìn)展[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2008年03期

4 薛青;;中醫(yī)藥治療晚期肝癌36例[J];遼寧中醫(yī)雜志;2009年04期

5 莫文娟;;從中醫(yī)五行觀點(diǎn)為肝癌術(shù)后綜合治療提供新思路[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2012年12期

6 吳繼萍;中醫(yī)藥防治肝癌的現(xiàn)狀與展望[J];安徽中醫(yī)臨床雜志;2003年02期

7 席玉才,李競;止痛奇效湯治療肝癌疼痛20例[J];中國中醫(yī)藥科技;2002年04期

8 朱忠才;杜鵬飛;;補(bǔ)腎疏肝法治療晚期肝癌腹水探析——“讀經(jīng)典,做臨床”之求本溯源治腹水[J];黑龍江中醫(yī)藥;2013年04期

9 盧麗華;虛靈功治愈肝癌一例[J];中國氣功;1997年07期

10 梁艷菊;鄧力;周蓓;;抑木扶土法治肝癌淺析[J];陜西中醫(yī);2008年09期

相關(guān)會議論文 前1條

1 賈文文;王彥剛;楊玉新;;肝癌晚期患者的中醫(yī)藥治療與護(hù)理[A];中華中醫(yī)藥學(xué)會脾胃病分會第二十三次全國脾胃病學(xué)術(shù)交流會論文匯編[C];2011年

相關(guān)重要報(bào)紙文章 前1條

1 黎國器;中西醫(yī)治肝癌各顯神通[N];上海中醫(yī)藥報(bào);2009年

，

本文編號：1436539